Kiora Pharmaceuticals, Inc.
KPRX
$2.50
-$0.08-3.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 9.39% | 18.46% | |||
| Gross Profit | -9.39% | -18.46% | |||
| SG&A Expenses | 0.98% | 6.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.56% | 11.38% | |||
| Operating Income | -4.56% | -11.38% | |||
| Income Before Tax | -1,062.83% | 72.78% | |||
| Income Tax Expenses | -1.07% | -473.68% | |||
| Earnings from Continuing Operations | -24,415.30% | 101.25% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -24,415.30% | 101.25% | |||
| EBIT | -4.56% | -11.38% | |||
| EBITDA | -4.58% | -11.08% | |||
| EPS Basic | -25,304.84% | 101.15% | |||
| Normalized Basic EPS | -9.46% | -2.19% | |||
| EPS Diluted | -25,304.84% | 101.15% | |||
| Normalized Diluted EPS | -11.29% | -0.51% | |||
| Average Basic Shares Outstanding | -2.79% | 7.54% | |||
| Average Diluted Shares Outstanding | -4.39% | 9.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||